You are here

Artificial Accessory Cell Bioreactor

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL131309-01
Agency Tracking Number: R43HL131309
Amount: $220,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: HL15-008
Timeline
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-08-15
Award End Date (Contract End Date): 2018-07-31
Small Business Information
130 N MAIN ST STE 600
Butte, MT 59701-9314
United States
DUNS: 836287680
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 TODD MCADAMS
 (406) 497-5233
 tmcadams@resodyn.com
Business Contact
 LAWRENCE FARRAR
Phone: (406) 497-5252
Email: lcfarrar@resodyn.com
Research Institution
N/A
Abstract

DESCRIPTION provided by applicant This Small Business Innovation Research Phase I project will develop and demonstrate a commercially feasible Artificial Accessory Cell Bioreactor AACB that can be used for translational research applications and scale up of stem cell cultures to support the development of emerging cell therapy applications The proposed bioreactor has two unique aspects The first component is a polymer microsphere based artificial accessory cell that will serve as a partial complete replacement for soluble cytokines and to mimic the stem cell niche for the system of interest The second component is a unique and extremely easy to use media replenishing bioreactor The Artificial Accessory Cells AACs will consist of polymer microspheres um functionalized with one or multiple cytokine peptide mimetic ECM and or other molecule depending on the needs of the particular stem cell culture system The focus of this proposal is the development and testing of the unique bioreactor which will incorporate use of the AACs as a key feature in advancing stem cell translational research While the AACB technology will be applicable to all types of stem cells for which some information on its biological niche is available the initial technology demonstration and suite of
products will be focused on hematopoietic stem cells HSCs because of the extensive knowledge and range of cytokines available for this well studied system Immobilization of biologically active factors is essential to achieving the goal of efficiently directing stem cells along desired pathways for therapeutic aims In vivo many important cytokines are presented in membrane bound or extra cellular matrix ECM bound forms Presentation in this format often induces a unique biological response on the target cell that cannot be duplicated using soluble forms of the molecule In addition this strategy may be effective for limiting the quantit of expensive signaling molecules necessary for large scale production of differentiated cells such as the production of red blood cells for transfusion in an ex vivo format The key to the proposed AACB productandapos s success will be process consistency ease of use and the development of approaches protocols and techniques that allow for the use of multiple cytokine types feed rates and modes of operation across a wide range of stem cell types

PUBLIC HEALTH RELEVANCE This Small Business Innovation Research Phase I project will develop a commercial Artificial Accessory Cell Bioreactor AACB to assist in translational research process control and scale up of stem cell expansion and differentiation for therapeutic applications In order to effectively scale up and reduce the costs of bringing stem cell therapies to the clinic more efficient means of providing the nutrients and growth factors needed to stimulate stem cells are needed The proposed bioreactor has the potential to increase the efficacy and stability of these factors while reducing the costs for large scale stem
cell production

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government